Eli Lilly and Company (NYSE:LLY) Stock Rating Upgraded by Wall Street Zen

Key Points

• Eli Lilly and Company has been upgraded from a "buy" rating to a "strong-buy" rating by Wall Street Zen.
• Analysts' ratings show a mix, with one strong buy, fourteen buy ratings, and nine hold ratings, resulting in an average rating of "Moderate Buy."
• In the most recent quarter, Eli Lilly reported $6.31 EPS, exceeding estimates, along with a 37.6% increase in revenue year-over-year to $15.56 billion.

Wall Street Zen upgraded shares of Eli Lilly and Company (NYSE:LLY - Free Report) from a buy rating to a strong-buy rating in a research report report published on Saturday morning.

Other equities analysts also recently issued research reports about the stock. Erste Group Bank downgraded shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. Hsbc Global Res upgraded Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research report on Wednesday. Cantor Fitzgerald lowered their price objective on Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating on the stock in a research report on Wednesday, August 13th. Daiwa America downgraded Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Sunday, August 17th. Finally, Daiwa Capital Markets downgraded Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price objective on the stock. in a research report on Sunday, August 17th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of "Moderate Buy" and a consensus price target of $950.17.

Eli Lilly and Company Stock Up 0.1%

Shares of NYSE LLY traded up $0.45 during midday trading on Friday, hitting $732.41. The stock had a trading volume of 2,548,350 shares, compared to its average volume of 6,895,566. The business's 50 day moving average is $748.68 and its 200-day moving average is $786.10. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $969.65. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The company has a market cap of $693.19 billion, a P/E ratio of 47.87, a PEG ratio of 1.02 and a beta of 0.44.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm's revenue for the quarter was up 37.6% on a year-over-year basis. During the same period in the previous year, the business earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be paid a $1.50 dividend. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. Eli Lilly and Company's dividend payout ratio is 39.22%.

Insider Transactions at Eli Lilly and Company

In other news, Director Jamere Jackson purchased 200 shares of the company's stock in a transaction on Friday, August 8th. The shares were acquired at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the purchase, the director owned 9,402 shares in the company, valued at $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Daniel Skovronsky purchased 1,000 shares of the company's stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the purchase, the executive vice president owned 137,660 shares in the company, valued at approximately $87,331,504. The trade was a 0.73% increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have bought 4,514 shares of company stock worth $2,894,841. Insiders own 0.13% of the company's stock.

Institutional Investors Weigh In On Eli Lilly and Company

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Redwood Investments LLC lifted its stake in Eli Lilly and Company by 0.5% in the fourth quarter. Redwood Investments LLC now owns 2,209 shares of the company's stock valued at $1,705,000 after acquiring an additional 12 shares during the last quarter. Hobbs Wealth Management LLC grew its stake in shares of Eli Lilly and Company by 0.8% in the first quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company's stock worth $1,205,000 after acquiring an additional 12 shares during the last quarter. Hixon Zuercher LLC increased its holdings in shares of Eli Lilly and Company by 0.7% during the 1st quarter. Hixon Zuercher LLC now owns 1,789 shares of the company's stock worth $1,477,000 after purchasing an additional 12 shares during the period. O Brien Wealth Partners LLC raised its holdings in Eli Lilly and Company by 25.5% in the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock valued at $49,000 after acquiring an additional 12 shares in the last quarter. Finally, Ascent Capital Management LLC raised its stake in shares of Eli Lilly and Company by 2.5% in the first quarter. Ascent Capital Management LLC now owns 495 shares of the company's stock valued at $409,000 after purchasing an additional 12 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.